{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:35:49Z","timestamp":1780925749468,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Autism spectrum disorder (ASD) is a complex range of neurodevelopmental disorders. The treatment of ASD is challenging since there are no approved drugs except for risperidone and aripiprazole, which have a limited effect on core symptoms and are associated with a wide range of adverse events. Bumetanide is a loop diuretic suggested to play a role in ASD symptoms by modulating the GABAergic system.\u00a0This meta-analysis aims to evaluate the efficacy and safety of bumetanide on ASD symptom management. We included randomized controlled trials comparing bumetanide with placebo or conventional treatment. Our primary outcomes included the Childhood Autism Rating Scale (CARS), Social Responsiveness Scale (SRS-2), Clinical Global Impression- Efficacy Index (CGI-EI), Social interaction (SI), repetitive behavior and restricted interests (RRB), and adverse events.\u00a0Bumetanide was associated with significant improvement in CARS total score (MD = -2.28; 95% CI = [-4.07, -0.49],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01) and CGI-EI (MD\u2009=\u20090.27; 95% CI = [0.09, 0.44],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003) compared to placebo. However, no significant difference was found in the SRS-2 score. Findings for SI and RRB were inconsistent depending on the pooled scales, with significant results observed when pooling SRS-2 but not when pooling ADOS. Bumetanide was generally safe and well-tolerated. Common adverse events include polyurea, hypokalemia, and dehydration.\u00a0Although statistically significant improvements were observed on some measures, we cannot conclude the superiority of bumetanide in alleviating ASD symptoms. Further large clinical trials should be conducted to determine the effect of bumetanide on different symptoms of ASD and the variation in treatment effect among different patient populations.\n                  <\/jats:p>","DOI":"10.1007\/s00787-025-02890-8","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:58:53Z","timestamp":1761825533000},"page":"413-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Efficacy and Safety of Bumetanide in Children with Autism Spectrum Disorder: An Updated Meta-analysis"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1201-0487","authenticated-orcid":false,"given":"Nada Ibrahim","family":"Hendi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereen A.","family":"Almosilhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Hany","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro Mamdouh","family":"Abdelrehim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Eisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba-tullah Ahmed Abouelkassem","family":"Saddoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelbassat","family":"Belakhdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2890_CR1","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. American Psychiatric Association. https:\/\/doi.org\/10.1176\/appi.books.9780890425596","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2890_CR2","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1007\/s10803-014-2163-1","volume":"44","author":"C Gillberg","year":"2014","unstructured":"Gillberg C, Fernell E (2014) Autism plus versus autism pure. J Autism Dev Disord 44:3274\u20133276. https:\/\/doi.org\/10.1007\/s10803-014-2163-1","journal-title":"J Autism Dev Disord"},{"key":"2890_CR3","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1111\/j.1651-2227.2010.01933.x","volume":"99","author":"E Lemonnier","year":"2010","unstructured":"Lemonnier E, Ben-Ari Y (2010) The diuretic bumetanide decreases autistic behaviour in five infants treated during 3\u2003months with no side effects. Acta Paediatr 99:1885\u20131888. https:\/\/doi.org\/10.1111\/j.1651-2227.2010.01933.x","journal-title":"Acta Paediatr"},{"key":"2890_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/children8050318","volume":"8","author":"HA Alsayouf","year":"2021","unstructured":"Alsayouf HA, Talo H, Biddappa ML, De Los Reyes E (2021) Risperidone or aripiprazole can resolve autism core signs and symptoms in young children: case study. Children 8:318. https:\/\/doi.org\/10.3390\/children8050318","journal-title":"Children"},{"key":"2890_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-017-0166-4","volume":"8","author":"J Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves J, Violante IR, Sereno J, Leit\u00e3o RA, Cai Y, Abrunhosa A (2017) Testing the excitation\/inhibition imbalance hypothesis in a mouse model of the autism spectrum disorder: in vivo neurospectroscopy and molecular evidence for regional phenotypes. Mol Autism 8:47. https:\/\/doi.org\/10.1186\/s13229-017-0166-4","journal-title":"Mol Autism"},{"key":"2890_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0692-2","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Huang C-C, Dai Y, Luo Q, Ji Y, Wang K et al (2020) Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA\/glutamate ratios. Transl Psychiatry 10:9. https:\/\/doi.org\/10.1038\/s41398-020-0692-2","journal-title":"Transl Psychiatry"},{"key":"2890_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.751575","author":"T Wang","year":"2021","unstructured":"Wang T, Shan L, Miao C, Xu Z, Jia F (2021) Treatment effect of bumetanide in children with autism spectrum disorder: a systematic review and meta-analysis. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2021.751575","journal-title":"Front Psychiatry"},{"key":"2890_CR8","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/aur.3005","volume":"16","author":"J Fuentes","year":"2023","unstructured":"Fuentes J, Parellada M, Georgoula C, Oliveira G, Marret S, Crutel V et al (2023) Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: results from two randomized phase\u2009<\u2009scp\u2009>\u2009III\u2009studies. Autism Res 16:2021\u20132034. https:\/\/doi.org\/10.1002\/aur.3005","journal-title":"Autism Res"},{"key":"2890_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71. n71","journal-title":"BMJ"},{"key":"2890_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"2890_CR11","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2890_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"2890_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.124","volume":"2","author":"E Lemonnier","year":"2012","unstructured":"Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M et al (2012) A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2:e202\u2013e202. https:\/\/doi.org\/10.1038\/tp.2012.124","journal-title":"Transl Psychiatry"},{"key":"2890_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/cap.2015.0045","volume":"25","author":"L Du","year":"2015","unstructured":"Du L, Shan L, Wang B, Li H, Xu Z, Staal WG et al (2015) A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism. J Child Adolesc Psychopharmacol 25:585\u2013588. https:\/\/doi.org\/10.1089\/cap.2015.0045","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2890_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.10","volume":"7","author":"E Lemonnier","year":"2017","unstructured":"Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M et al (2017) Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry 7:e1056\u2013e1056. https:\/\/doi.org\/10.1038\/tp.2017.10","journal-title":"Transl Psychiatry"},{"key":"2890_CR16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","volume":"60","author":"JJ Sprengers","year":"2021","unstructured":"Sprengers JJ, van Andel DM, Zuithoff NPA, Keijzer-Veen MG, Schulp AJA, Scheepers FE et al (2021) Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. J Am Acad Child Adolesc Psychiatry 60:865\u2013876. https:\/\/doi.org\/10.1016\/j.jaac.2020.07.888","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2890_CR17","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.scib.2021.01.008","volume":"66","author":"Y Dai","year":"2021","unstructured":"Dai Y, Zhang L, Yu J, Zhou X, He H, Ji Y et al (2021) Improved symptoms following bumetanide treatment in children aged 3\u2009\u2013\u20096 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. Sci Bull 66:1591\u20131598. https:\/\/doi.org\/10.1016\/j.scib.2021.01.008","journal-title":"Sci Bull"},{"key":"2890_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2174\/1871527322666230404114911","volume":"23","author":"E Shaker","year":"2024","unstructured":"Shaker E, Agami O, El SA (2024) Bumetanide, a diuretic that can help children with autism spectrum disorder. CNS Neurol Disord Drug Targets 23:536\u2013542. https:\/\/doi.org\/10.2174\/1871527322666230404114911","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2890_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00787-021-01772-z","volume":"31","author":"L Jurek","year":"2022","unstructured":"Jurek L, Baltazar M, Gulati S, Novakovic N, N\u00fa\u00f1ez M, Oakley J et al (2022) Response (minimum clinically relevant change) in ASD symptoms after an intervention according to CARS-2: consensus from an expert elicitation procedure. Eur Child Adolesc Psychiatry 31:1\u201310. https:\/\/doi.org\/10.1007\/s00787-021-01772-z","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2890_CR20","doi-asserted-by":"publisher","unstructured":"Mollajani R, Joghataei MT, Tehrani-doost M (2019) Bumetanide therapeutic effect in children and adolescents with autism spectrum disorder: a review study. Basic Clin Neurosci J 433\u2013442. https:\/\/doi.org\/10.32598\/bcn.9.10.380","DOI":"10.32598\/bcn.9.10.380"},{"key":"2890_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrn3857","volume":"16","author":"LQ Uddin","year":"2015","unstructured":"Uddin LQ (2015) Salience processing and insular cortical function and dysfunction. Nat Rev Neurosci 16:55\u201361. https:\/\/doi.org\/10.1038\/nrn3857","journal-title":"Nat Rev Neurosci"},{"key":"2890_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/frcha.2024.1236340","author":"N Hawken","year":"2024","unstructured":"Hawken N, Falissard B, Choquet C, Francois C, Tardu J, Schmid R (2024) Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder. Front Child Adolesc Psychiatry. https:\/\/doi.org\/10.3389\/frcha.2024.1236340","journal-title":"Front Child Adolesc Psychiatry"},{"key":"2890_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/1362361314542955","volume":"19","author":"E Anagnostou","year":"2015","unstructured":"Anagnostou E, Jones N, Huerta M, Halladay AK, Wang P, Scahill L et al (2015) Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism 19:622\u2013636. https:\/\/doi.org\/10.1177\/1362361314542955","journal-title":"Autism"},{"key":"2890_CR24","doi-asserted-by":"publisher","unstructured":"Constantino JN (2013) Social responsiveness Scale. Encyclopedia of autism spectrum disorders. Springer New York, New York, NY, pp 2919\u20132929. https:\/\/doi.org\/10.1007\/978-1-4419-1698-3_296","DOI":"10.1007\/978-1-4419-1698-3_296"},{"key":"2890_CR25","doi-asserted-by":"publisher","unstructured":"Evans P, Golla S, Ann Morris M (2015) Autism spectrum disorders. Rosenberg\u2019s molecular and genetic basis of neurological and psychiatric disease. Elsevier, pp 197\u2013207. https:\/\/doi.org\/10.1016\/B978-0-12-410529-4.00018-8","DOI":"10.1016\/B978-0-12-410529-4.00018-8"},{"key":"2890_CR26","unstructured":"Cochrane Training Chapter 10: analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions"},{"key":"2890_CR27","doi-asserted-by":"publisher","unstructured":"Kanters S (2022) Fixed- random-effects models. 41\u201365. https:\/\/doi.org\/10.1007\/978-1-0716-1566-9_3","DOI":"10.1007\/978-1-0716-1566-9_3"},{"key":"2890_CR28","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1177\/1362361318824103","volume":"23","author":"AY Hardan","year":"2019","unstructured":"Hardan AY, Hendren RL, Aman MG, Robb A, Melmed RD, Andersen KA et al (2019) Efficacy and safety of memantine in children with autism spectrum disorder: results from three phase 2 multicenter studies. Autism 23:2096\u20132111. https:\/\/doi.org\/10.1177\/1362361318824103","journal-title":"Autism"}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-025-02890-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-025-02890-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-025-02890-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:02:56Z","timestamp":1772578976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-025-02890-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2890"],"URL":"https:\/\/doi.org\/10.1007\/s00787-025-02890-8","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This article is based on previously conducted studies and does not contain any current intervention with human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical consideration"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}